VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?

Key Takeaways Alyftrek sales jumped to $247M, beating estimates and showing strong global launch momentum.Journavx brought in $19.6M, meeting targets as prescriptions and payer coverage expand steadily.Casgevy sales fell 44% sequentially to $16.9M, though patient access and reimbursement are improving.Vertex Pharmaceuticals Incorporated’s (VRTX) third-quarter 2025 results were strong as it beat estimates for both earnings and sales.The company’s total revenues of $3.08 billion rose 11% year over year, drive ...